Ocular Therapeutix outlines Q4 2026 AXPAXLI NDA plan with $530.6M cash runway into 2028

Summary

Ocular Therapeutix has outlined a plan for a new drug application (NDA) for its AXPAXLI product in the fourth quarter of 2026, alongside a cash runway of $530.6 million extending into 2028, according to a Seeking Alpha breaking news headline. The report is based on the headline alone, so no further details on the NDA's contents, timing drivers or the company's reasoning are available from the article provided.

Timeline

1. Seeking Alpha

   9 Nov 2026, 17:51 UTCSource ↗

   Reports that Ocular Therapeutix outlined a Q4 2026 NDA plan for AXPAXLI with $530.6M cash runway into 2028.